HC Wainwright Has Positive Estimate for GRI Bio Q3 Earnings

GRI Bio, Inc. (NASDAQ:GRI) – Research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for GRI Bio in a report issued on Thursday, September 10th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings of ($0.75) per share for the quarter, up from their prior forecast of ($0.95). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for GRI Bio’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for GRI Bio’s Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.36) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.17) EPS.

Several other equities analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a research report on Friday, July 17th. Ascendiant Capital Markets decreased their target price on shares of GRI Bio from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, GRI Bio currently has an average rating of “Hold” and a consensus target price of $21.00.

GRI Bio Stock Performance

Shares of NASDAQ GRI opened at $1.82 on Monday. The business has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $2.09. GRI Bio has a 52 week low of $1.36 and a 52 week high of $64.12. The stock has a market cap of $3.99 million, a price-to-earnings ratio of -0.05 and a beta of -1.24.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.28.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.